Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 31;9:723817. doi: 10.3389/fcell.2021.723817

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Huang, Liu, Zhu, Jin, Chen, Xu, Cheng, Ruan, Su, Meng, Lu and Yan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The relationship between the ICI score and antitumor immunity and the role of ICI pattern in anti-PD-L1 immunotherapy. (A) The difference of the number of neoantigens in the high and low ICI score groups (Wilcoxon test, p = 0.079). (B) The comparison of the ICI score in different anti-PD-1 clinical response statuses (Wilcoxon test, p = 0.003). (C) Kaplan–Meier curves for patients in the high and low ICI score group in the IMvigor210 cohort (log-rank test, p = 0.016). (D) The rate of clinical response to anti-PD-L1 immunotherapy in the high and low ICI score groups in the IMvigor210 cohort (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease).